Skip to main content
News

Galinpepimut-S Reduces Risk of Death by 41% in Acute Myeloid Leukemia Following Second Remission

Edited by 

Clinical Summary: 

  • Design/Population: The open-label, phase 3 REGAL trial evaluated galinpepimut-S, an investigational WT1-targeted immunotherapeutic cancer vaccine, versus investigator-selected best available treatment in patients with acute myeloid leukemia (AML) who achieved a second or later complete remission or complete remission with insufficient platelet recovery following salvage therapy and were ineligible for or unable to undergo allogeneic stem cell transplantation.

  • Key Outcomes: Galinpepimut-S significantly improved overall survival (OS) compared with best available treatment, reducing the risk of death by 41%. Median OS was 24 months and 14.7 months, respectively. Treatment-related adverse events were predominantly grade 1 or 2, with no new safety signals identified.

  • Clinical Relevance: These findings support galinpepimut-S as a potential maintenance treatment option for patients with AML in second or later remission who cannot undergo allogeneic stem cell transplantation, addressing an unmet need for therapies that prolong survival in this high-risk population.

Results from the phase 3 REGAL trial demonstrated that galinpepimut-S, an investigational WT1-targeted immunotherapeutic cancer vaccine, significantly improved overall survival (OS) compared with investigator-selected best available treatment in patients with acute myeloid leukemia (AML) in second or later remission who were unable to undergo allogeneic stem cell transplantation. 

In this open-label trial, 126 patients with AML who achieved a second or later complete remission or complete remission with insufficient platelet recovery following second- or later-line salvage therapy were randomized 1:1 to receive galinpepimut-S maintenance monotherapy or investigator-selected best available treatment.

Eligible patients were ineligible for or unable to undergo allogeneic stem cell transplantation. Best available treatment consisted of observation, a hypomethylating agent, venetoclax, and/or low-dose cytarabine.

The primary end point was OS from study entry. Key secondary end points included safety and tolerability, leukemia-free survival, landmark OS and relapse-free survival in patients with prior allogeneic transplantation, antigen-specific T-cell immune responses, measurable residual disease, and additional molecular and clinical assessments.

The primary efficacy analysis was conducted following the prespecified occurrence of 80 deaths, in accordance with the trial's statistical analysis plan.

At analysis, median OS was 24 months in the galinpepimut-S arm and 14.7 months in the best available treatment arm, reducing the risk of death by 41% (hazard ratio [HR], 0.59; two-sided P = .035).

These findings met the trial's primary end point, demonstrating a statistically significant OS benefit with galinpepimut-S maintenance therapy compared with investigator-selected best available treatment.

The treatment groups were reported to be well balanced for prognostic stratification factors. A limited number of patients subsequently underwent hematopoietic stem cell transplantation, with similar numbers in both treatment arms.

Galinpepimut-S was generally well tolerated, with a safety profile consistent with previous clinical experience and no new safety signals identified.

Treatment-related adverse events were predominantly grade 1/2, with local injection-site reactions representing the most commonly reported events. Detailed safety findings, including rates of grade ≥3 adverse events and treatment discontinuations, were not provided in the topline announcement.

Galinpepimut-S is an investigational immunotherapeutic cancer vaccine composed of 4 WT1-derived peptides designed to stimulate CD4-positive and CD8-positive T-cell immune responses against WT1-expressing cancer cells.

Based on the positive findings, SELLAS plans to meet with the US Food and Drug Administration (FDA) to discuss a potential accelerated filing strategy and advance preparations for a biologics license application submission during the first half of 2027.

Additional analyses of secondary end points and other prespecified outcomes remain ongoing, with comprehensive findings expected to be presented at a future medical conference and submitted for peer-reviewed publication.


Source: 

SELLAS Life Science Group. SELLAS Life Sciences Announces positive pivotal phase 3 REGAL trial data showing immunotherapeutic cancer vaccine, Galinpepimut-S (GPS), demonstrated a statistically significant and clinically meaningful improvement in overall survival in patients with acute myeloid leukemia. Accessed on: November 19, 2026. https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Announces-Positive-Pivotal-Phase-3-REGAL-Trial-Data-Showing-Immunotherapeutic-Cancer-Vaccine-Galinpepimut-S-GPS-Demonstrated-a-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Overall-Survival-in-Patients-with-A/default.aspx

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.